Search in:

Advanced search

Clinical Ophthalmology Volume 5, 2011 - Issue

Submit an article Journal homepage

Open access

204

Views

CrossRef citations to date

Altmetric

Original Research

Pharmacokinetics of intravitreal bevacizumab (Avastin^®) in rabbits

Christos I Sinapis1 Laboratory for Experimental Surgery and Surgical Research ‘N.S.Christeas’Correspondence[email protected]

John G Routsias2 Laboratory of Pathophysiology

Angelos I Sinapis1 Laboratory for Experimental Surgery and Surgical Research ‘N.S.Christeas’

Dimitrios I Sinapis1 Laboratory for Experimental Surgery and Surgical Research ‘N.S.Christeas’

George D Agrogiannis3 Laboratory of Pathology

Alkistis Pantopoulou1 Laboratory for Experimental Surgery and Surgical Research ‘N.S.Christeas’

Stamatis E Theocharis4 Laboratory of Forensic Medicine and Toxicology

Stefanos Baltatzis5 Department of Ophthalmology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece

Efstratios Patsouris3 Laboratory of Pathology

Despoina Perrea1 Laboratory for Experimental Surgery and Surgical Research ‘N.S.Christeas’

show all

Pages 697-704 | Published online: 24 May 2011

Cite this article

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

References

HurwitzHFehrenbacherLNovotnyWBevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancerN Engl J Med20043502335234215175435
PubMed Web of Science ®Google Scholar
MordentiJCuthbertsonRAFerraraNComparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125l-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administrationToxicol Pathol19992753654410528633
PubMed Web of Science ®Google Scholar
ShaharJAveryRLHeilweilGElectrophysiologic and retinal penetration studies following intravitreal administration of bevacizumab (Avastin)Retina20062626226916508424
PubMed Web of Science ®Google Scholar
DibEduardoMaiaMauricioLongo-MaugeriIeda MariaSubretinal Bevacizumab Detection after Intravitreous Injection in RabbitsInvest Ophthalmol Vis Sci2008491097110018326736
PubMed Web of Science ®Google Scholar
MichelsSRosenfeldPJPuliafitoCAMarcusENVenkatramanASSystemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve week results of an uncontrolled open-label clinical studyOphthalmology20051121035104715936441
PubMed Web of Science ®Google Scholar
LadewigMSZiemssenFJaissleGIntravitreal bevacizumab for neovascular age-related macular degenerationOphthalmologe200610346347016763862
PubMed Web of Science ®Google Scholar
HaritoglouCKookDNeubauerAIntravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edemaRetina200626999100517151486
PubMed Web of Science ®Google Scholar
Diabetic Retinopathy Clinical Research NetworkScottIUEdwardsARBeckRWA phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edemaOphthalmology20071141860186717698196
PubMed Web of Science ®Google Scholar
AveryRLPearlmanJPieramiciDJIntravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathyOphthalmology20061131695170517011951
PubMed Web of Science ®Google Scholar
JaissleGBZiemssenFPetermeierKBevacizumab for treatment of macular edema secondary to retinal vein occlusionOphthalmologe200610347147516763863
PubMed Web of Science ®Google Scholar
PriglingerSGWolfAHKreutzerTCIntravitreal bevacizumab injections for treatment of central retinal vein occlusion: six-month results of a prospective trialRetina2007271004101218040236
PubMed Web of Science ®Google Scholar
RosenfeldPJMoshfeghiAAPuliafitoCAOptical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusionOphthalmic Surg Lasers Imaging20053633133516156152
PubMed Web of Science ®Google Scholar
BakriSJSnyderMRReidJMPulidoJSSinghRJPharmacokinetics of intravitreal bevacizumab (Avastin)Ophthalmology200711485585917467524
PubMed Web of Science ®Google Scholar
NomotoHShiragaFKunoNPharmacokinetics of bevacizumab after topical, sub conjunctival, and intravitreal administration in rabbitsInvest Ophthalmol Vis Sci2009504807481319324856
PubMed Web of Science ®Google Scholar
ZhuQiZiemssenFockeHenke-FahleSigridVitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularizationOphthalmology20081151750175518708261
PubMed Web of Science ®Google Scholar
YanyaliAAytugBHorozogluFNohutcuAFBevacizumab (Avastin) for diabetic macular edema in previously vitrectomized eyesAm J Ophthalmol200714412412617601433
PubMed Web of Science ®Google Scholar
WangYFeiDVanderlaanMSongABiological activity of bevacizumab, a humanized anti-VEGF antibody in vitroAngiogenesis2004733534515886877
PubMedGoogle Scholar
IyerMNHeFWenselTGClearance of intravitreal moxifloxacinInvest Ophthalmol Vis Sci20064731731916384979
PubMed Web of Science ®Google Scholar
FauserSKalbacherHAlteheldNPharmacokinetics and safety of intravitreally delivered etanerceptGraefes Arch Clin Exp Ophthalmol200424258258615029504
PubMed Web of Science ®Google Scholar
ScholesGNO’ BrienWJAbramsGWKubicekMFClearance of triamcinolone from vitreousArch Ophthalmol1985103156715694051860
PubMed Web of Science ®Google Scholar
KrohneTEterNHolzFMeyerCIntraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humansAm J Ophthalmol200814650851218635152
PubMed Web of Science ®Google Scholar
ChinHSParkTSMoonYSOhJHDifference in clearance of intravitreal triamcinolone acetonide between vitrectomized and nonvitrectomized eyesRetina20052555656016077349
PubMed Web of Science ®Google Scholar
BeerPMBakriSJSinghRJIntraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injectionOphthalmology200311068168612689886
PubMed Web of Science ®Google Scholar
European Medicines Agency (EMEA)Avastin (bevacizumab): scientific discussion Available at: http://www.emea.europa.eu/humandocs/PDFs/EPAR/avastin/17199204en6.pdf. Accessed September 28, 2007.
Google Scholar
European Medicines Agency (EMEA)Lucentis (ranibizumab): scientific discussion Available at: http://www.emea.europa.eu/humandocs/PDFs/EPAR/lucentis/H-715-EN6.pdf. Accessed September 28, 2007.
Google Scholar
BakriSJSnyderMRReidJMPulidoJSEzzatMKSinghRJPharmacokinetics of intravitreal ranibizumab (Lucentis)Ophthalmology20071142179218218054637
PubMed Web of Science ®Google Scholar
GaudreaultJFeiDRusitJSubocPShiuVPreclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administrationInvest Ophthalmol Vis Sci20054672673315671306
PubMed Web of Science ®Google Scholar

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Pharmacokinetics of intravitreal bevacizumab (Avastin^®) in rabbits

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Pharmacokinetics of intravitreal bevacizumab (Avastin®) in rabbits

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Pharmacokinetics of intravitreal bevacizumab (Avastin^®) in rabbits